Physician profile
Stanley Cheng
NPI 1063916567
$16,152.91
in general payments reported to CMS, 2019-2025
28 companies · $9,341 in 2025
The $9,341 reported for 2025 was more than what 88% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.07 · 2021: $228 · 2022: $1,647 · 2023: $1,727 · 2024: $3,140 · 2025: $9,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,972 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,890 · Consulting Fee: $1,446 · Grant: $800 · Education: $75.07 · Travel and Lodging: $24.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,972.29 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,890.00 |
| Consulting Fee | $1,446.00 |
| Grant | $800.00 |
| Education | $75.07 |
| Travel and Lodging | $24.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $6,780.33 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,584.33 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Regeneron Pharmaceuticals, INC. | $1,026.61 | 2022-2025 | Dupixent |
| Csl Behring | $882.04 | 2022-2025 | Hizentra, Andembry, Haegarda |
| Takeda Pharmaceuticals U.S.A., INC. | $547.59 | 2023-2025 | Cuvitru, Takhzyro, Eohilia |
| Glaxosmithkline, LLC. | $538.87 | 2022-2025 | Nucala, Trelegy Ellipta |
| Amgen INC. | $537.64 | 2022-2025 | Tezspire, Actimmune |
| Novartis Pharmaceuticals Corporation | $381.27 | 2025 | |
| Pharming Healthcare, INC. | $358.43 | 2022-2025 | Ruconest |
| Regeneron Healthcare Solutions, INC. | $358.27 | 2024-2025 | Dupixent |
| Alk-Abello, INC | $274.41 | 2023-2025 | Odactra, Grastek, Ragwitek |
| Genentech USA, INC. | $259.05 | 2024-2025 | Xolair |
| Biocryst US Sales Co., LLC | $243.58 | 2021-2025 | Orladeyo |
| Blueprint Medicines Corporation | $232.50 | 2023-2025 | Ayvakit |
| Grifols USA, LLC | $203.38 | 2021-2025 | Xembify |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $176.12 | 2023-2024 | |
| Ars Pharmaceuticals Operations, INC. | $170.80 | 2025 | Neffy |
| Ionis Pharmaceuticals, INC. | $125.80 | 2025 | Dawnzera |
| Optinose US, INC. | $112.16 | 2023 | |
| Lilly USA, LLC | $83.25 | 2024-2025 | Ebglyss, Zepbound |
| Sanofi-Aventis U.S. LLC | $59.80 | 2025 | |
| Organon LLC | $48.61 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $37.18 | 2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.13 | 2022 | |
| Incyte Corporation | $28.34 | 2024 | Opzelura |
| Azurity Pharmaceuticals, INC. | $25.85 | 2025 | Alvesco |
| Phadia US INC. | $22.07 | 2024 | Immunocap |
| Arcutis Biotherapeutics, INC. | $19.50 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.